Stocks · News reference
Compugen Q2 EPS $(0.07), Inline, Sales $2.602M Beat $1.606M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 12.5 percent increase over losses of $(0.08) per share from the same period last year. The
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 11:01 AM
- Checked
- Aug 3, 2026, 11:01 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Compugen To Present Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701, Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a
Read original at benzingaCompugen Q1 2026 Earnings Call: Complete Transcript
Read original at benzinga